Immunomodulatory therapy for melanoma: ipilimumab and beyond
about
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionInhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataThe importance of animal models in tumor immunity and immunotherapyColorectal cancer immunotherapy.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustionInhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaBlockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma.Deoxyarbutin displays antitumour activity against melanoma in vitro and in vivo through a p38-mediated mitochondria associated apoptotic pathway.Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells
P2860
Q26777563-900E265F-2DD5-4C8F-B0C6-567FD82CEB5FQ26781098-3D81CC05-B20C-4E0E-BE3E-4FDDA887CCCFQ26823861-F8AC9F6B-B2BE-437A-8603-DEA6E973AA83Q33701465-5E27E50C-21C8-430A-9B29-2537A4A1C2A5Q34000700-1AA7F625-41B1-48CD-AF42-F39880AA4050Q34626229-46E88819-064E-4ECC-83FD-3B73603EF728Q36616174-FE796BFD-D427-4584-AC4F-6A26C0F9F795Q37267697-D290A0E7-335F-4537-9D0C-DB027A59B4F4Q37448109-B46FD69C-0E9B-4619-97ED-4EBDA94C01DAQ38299845-3F853BEF-AD1F-4DCD-BFA7-D65A034E1057Q38577834-7FC4DCB3-FA55-4D36-BE17-FAC618F70F75Q39004691-04129568-ADC2-4762-BD32-2FF9DA357F4DQ40340021-1FFFB0DE-4351-4411-8C0D-2F0F014C31ABQ40755959-EE5D3AAF-CB7C-49F4-BB8C-7F8D0AD4A1FEQ41244524-1ED10EFD-80C4-4B61-852D-B925CA1E8C2EQ47178368-317C7F89-FA4D-4FA7-B720-5AA40E03F82BQ57788678-94BA8343-CC6C-46B5-B15B-8633A1E5D30F
P2860
Immunomodulatory therapy for melanoma: ipilimumab and beyond
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunomodulatory therapy for melanoma: ipilimumab and beyond
@en
type
label
Immunomodulatory therapy for melanoma: ipilimumab and beyond
@en
prefLabel
Immunomodulatory therapy for melanoma: ipilimumab and beyond
@en
P2093
P2860
P1476
Immunomodulatory therapy for melanoma: ipilimumab and beyond
@en
P2093
Jedd D Wolchok
Margaret K Callahan
Michael A Postow
P2860
P304
P356
10.1016/J.CLINDERMATOL.2012.08.006
P577
2013-03-01T00:00:00Z